Shay Shemesh
Founder at NUVECTIS PHARMA, INC.
Net worth: 10 M $ as of 30/04/2024
Shay Shemesh active positions
Companies | Position | Start | End |
---|---|---|---|
NUVECTIS PHARMA, INC. | Chief Operating Officer | 27/07/2020 | - |
Founder | 27/07/2020 | - | |
Corporate Officer/Principal | 27/07/2020 | - |
Career history of Shay Shemesh
Former positions of Shay Shemesh
Companies | Position | Start | End |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2015 | 01/01/2020 |
General Counsel | 01/01/2015 | 01/01/2020 | |
KERYX BIOPHARMACEUTICALS | Chief Tech/Sci/R&D Officer | - | - |
Training of Shay Shemesh
Bar-Ilan University | Graduate Degree |
Statistics
International
United States | 4 |
Israel | 2 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
NUVECTIS PHARMA, INC. | Health Technology |
Private companies | 2 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Shay Shemesh
- Experience